Boston Scientific's Q1 2026 Earnings: What to Expect

Core Viewpoint - Boston Scientific Corporation (BSX) is a leading medical device company with a market cap of $102.8 billion, focusing on various interventional medical specialties and addressing unmet clinical needs across multiple complex conditions [1] Financial Performance - Analysts expect BSX to report a profit of $0.80 per share for fiscal Q1 2026, reflecting a 6.7% increase from $0.75 per share in the same quarter last year [2] - For the current fiscal year ending in December, BSX is projected to report a profit of $3.45 per share, which is a 12.8% increase from $3.06 per share in fiscal 2025 [3] - The company's EPS is anticipated to grow by 13% year-over-year to $3.90 in fiscal 2027 [3] Earnings History - BSX has consistently exceeded Wall Street's bottom-line estimates in the last four quarters, with reported earnings of $0.80 per share in the previous quarter surpassing forecasts by 2.6% [2] - The earnings history shows a positive surprise trend, with the most recent quarter (ending December 2025) reporting a surprise of +2.56% against an estimate of $0.78 [4] Stock Performance - Over the past 52 weeks, BSX shares have declined by 31.4%, underperforming the S&P 500 Index's return of 11.9% and the State Street Health Care Select Sector SPDR ETF's drop of 1.2% [4] - Year-to-date, BSX shares have decreased by approximately 27.5%, with a significant drop of 17.6% following the release of its fourth-quarter results on February 4 [5] Market Sentiment - Despite solid operational performance, including a 15.9% year-over-year increase in net sales to $5.3 billion, investor sentiment has shifted due to management's guidance for the first quarter being slightly below Wall Street expectations [5][6]